PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: PMR Corporate

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

The Clinical Trials Market in Poland Growing At A Moderate Pace Finds PMRCorporate - According to the most recent PMR report, “Clinical trials in Poland 2012. Development forecasts for 2012-2014”, the clinical trials market in Poland will grow at a moderate pace, by approximately 5% per annum, to PLN 860m (approximately €200m)
The Clinical Trials Market in Poland Growing At A Moderate Pace Finds PMRCorporate

 

NewswireToday - /newswire/ - Cracow, Malopolskie, Poland, 2012/06/26 - According to the most recent PMR report, “Clinical trials in Poland 2012. Development forecasts for 2012-2014”, the clinical trials market in Poland will grow at a moderate pace, by approximately 5% per annum, to PLN 860m (approximately €200m).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

in 2014. Poland will remain one of the most attractive countries in the Central and Eastern Europe region because of the large population of patients willing to participate in clinical research (access to innovative treatment is poor in Poland) and the superior quality of the infrastructure associated with the conducting of clinical trials.

Reimbursement Act affects also clinical trials
Between 2009 and 2010 the clinical trials market stagnated and displayed a low rate of growth of about 1-2%. This was definitely a result of the economic crisis, which led to a reduction in spending on R&D projects and thus on clinical trials.

We estimate that in 2011 the clinical trials market on which companies carry out phase I-IV clinical trials of drugs and bioequivalence tests was worth PLN 756m (€184m). In comparison with 2010, the value of the market had increased by 7%. The Polish clinical trials market is relatively saturated, and we do not expect to see substantial growth. We predict that between 2012 and 2013 annual growth will be around 3-4%. The CAGR (Compound Annual Growth Rate) for the Polish market between 2012 and 2014 will be around 5%. This modest increase can also be attributed, to some extent, to the extreme change in the Polish reimbursement system, which has made the operation of the pharmaceutical market in Poland very difficult, particularly for innovative companies. They will prefer to focus on new marketing and reimbursement strategies instead of clinical trials, and the unfavourable innovation climate could discourage them from carrying out R&D activity. In 2014, the situation will improve slightly in the wake of adjustment to the new market conditions and because of the proposed Act on Clinical Trials, which is expected to bring some order to the market.

Legal environment still in need of codification
Whereas Polish companies do not spend excessive amounts on research and development, the domestic pharmaceutical industry leads the field in the industrial arena in terms of the number of innovative companies, according to the Gdansk Institute for Market Economics (IBnGR). 56% of pharmaceutical companies carried out innovative projects between 2007 and 2009, either investing in the development of pharmaceuticals or upgrading their production facilities.
Representatives of companies involved in clinical trials in Poland surveyed specifically for the purposes of the report believe that one factor which could affect market growth more than any other over the next few years will be the “tidying up” of the relevant legislation. This has been the most important factor for the second consecutive edition of the survey. Respondents indicated measures such as the need to ratify the law on clinical trials, which should include the introduction of safeguards not only for the researcher but also for the patient, along with an increase in the transparency of the trial authorisation process.

In 2012, as in previous years, the most significant factor which could have an effect on market development is the continued simplification of the trial registration procedure at the CEBK (Central Register of Clinical Trials). However, this view was taken by considerably fewer respondents than in 2006 and 2008.

Many more respondents than in the previous editions of the survey suggested that the need to clarify contractual issues was an essential factor in the development of the clinical trials market in Poland. This issue could be resolved by regulating matters pertaining to contracts between sponsors, investigators and trial centres. The Health Ministry plans to introduce these changes as part of the draft Clinical Trials Law.

This press release is based on information contained in the latest PMR report entitled “Clinical trials in Poland 2012. Development forecasts for 2012-2014”.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: PMR Corporate

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


The Clinical Trials Market in Poland Growing At A Moderate Pace Finds PMRCorporate

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: PMRCorporate.com 
+48 12 618 90 00 marketing[.]pmrcorporate.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PMR Corporate securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From PMR Corporate / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)